Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

Table 6

Clinical outcomes at two years.

	Italy		Spain		Sweden
	Doxorubicin/ifosfamide	Trabectedin	Doxorubicin/ifosfamide	Trabectedin	Doxorubicin/ifosfamide	Trabectedin
Probability of
complete response	0.01	<0.01	<0.01	<0.01	<0.01	0.01
partial response	0.01	<0.01	0.01	<0.01	0.01	0.01
stable disease	0.02	0.01	0.02	0.01	0.02	0.01
progressive disease	0.54	0.51	0.54	0.53	0.54	0.59
dying	0.43	0.47	0.42	0.45	0.42	0.39
Number of QALYs per patient	0.595 (0.593, 0.597)	0.530 (0.528, 0.533)	0.590 (0.587, 0.593)	0.550 (0.547, 0.553)	0.608 (0.606, 0.611)	0.584 (0.582, 0.587)

95% confidence intervals in parentheses.